Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jagsonpal Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	-	100.42	110.28	127.6	110.53	225.26
Short-Term Investments	-	957.64	1,175	1,352	1,036	245.31
Cash & Short-Term Investments	1,061	1,058	1,285	1,479	1,146	470.57
Cash Growth	-17.57%	-17.69%	-13.11%	29.06%	143.59%	-24.34%
Accounts Receivable	-	171.91	131.76	109.51	208.72	155.77
Receivables	-	171.91	131.76	109.51	208.72	155.77
Inventory	-	146.43	152	149.97	206.76	297.42
Prepaid Expenses	-	16.63	16.62	16.02	10.68	10.62
Other Current Assets	-	37.86	26.11	212.95	73.17	156.43
Total Current Assets	-	1,431	1,612	1,968	1,646	1,091
Property, Plant & Equipment	-	73.5	88.37	93.02	242.78	225.73
Long-Term Investments	-	845.32	168.62	47	33.84	290.55
Goodwill	-	96.93	96.93	-	-	0.3
Other Intangible Assets	-	682.67	759.24	-	-	-
Other Long-Term Assets	-	37.46	57.5	62.97	27.25	34.86
Total Assets	-	3,167	2,783	2,171	1,949	1,642

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	-	115.81	97.34	75.96	165.8	185.5
Accrued Expenses	-	115.69	112.13	81.71	88.86	79.86
Current Portion of Leases	-	15.76	16.07	13.84	7.54	-
Current Income Taxes Payable	-	5.57	-	-	0.19	2.33
Current Unearned Revenue	-	9.35	9.1	12.94	6.12	-
Other Current Liabilities	-	20.8	24.4	6.83	7.2	2.03
Total Current Liabilities	-	282.98	259.04	191.28	275.71	269.72
Long-Term Leases	-	65.89	76.32	75.57	52.47	-
Long-Term Deferred Tax Liabilities	-	44.41	30.7	20.73	21.63	32.38
Other Long-Term Liabilities	-	11.77	17.04	9.18	10.75	12.56
Total Liabilities	-	405.05	383.1	296.76	360.56	314.66

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	-	133.93	132.8	132.19	130.99	130.99
Additional Paid-In Capital	-	248.64	140.56	111.2	6	6
Retained Earnings	-	2,174	1,906	1,460	1,363	1,112
Comprehensive Income & Other	-	204.78	219.65	170.7	88.52	78.87
Shareholders' Equity	2,762	2,762	2,400	1,874	1,589	1,328
Total Liabilities & Equity	-	3,167	2,783	2,171	1,949	1,642

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	81.65	81.65	92.39	89.41	60.01	-
Net Cash (Debt)	979.55	976.41	1,193	1,390	1,086	470.57
Net Cash Growth	-18.02%	-18.16%	-14.16%	27.96%	130.84%	-15.07%
Net Cash Per Share	14.44	14.31	17.72	20.96	16.59	7.18
Filing Date Shares Outstanding	65.95	66.96	66.4	66.09	65.5	65.5
Total Common Shares Outstanding	65.95	66.96	66.4	66.09	65.5	65.5
Working Capital	-	1,148	1,353	1,777	1,370	821.09
Book Value Per Share	39.40	41.24	36.14	28.35	24.26	20.27
Tangible Book Value	1,982	1,982	1,543	1,874	1,589	1,327
Tangible Book Value Per Share	28.28	29.60	23.24	28.35	24.26	20.27
Land	-	-	-	-	87.59	87.59
Buildings	-	-	-	-	163.8	163.8
Machinery	-	16.25	14.77	20.38	18.02	329.61

Data Source: S&P Global Market Intelligence Last updated: Jul 29, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 9, 2026

Data Sources Report a data error